Anesthetic challenges in the management of Larsen syndrome: A rare congenital anomaly.

Larsen syndrome is a rare inherited disease associated with dislocations of multiple joints, typical syndromic facies, and multiple spine abnormalities. They often required multiple corrective orthopedic surgeries to regain their functional ability, thus needing repeated anesthesia. Apart from skeletal deformities, they have predicted difficult airway and need extreme care during intubation and positing of the patient. Abnormal posturing due to spinal deformity and poor pulmonary reserve due to kyphoscoliosis creates an extremely challenging situation for the anesthetist to manage the case during the perioperative period. Here we are describing the perioperative anesthetic management of a patient with Larsen syndrome.

The effect of perioperative dexmedetomidine on postoperative bowel function recovery in adult patients receiving general anesthesia.

BACKGROUND: Dexmedetomidine has opioid sparing actions but its effect on bowel recovery is controversial. Primary aim of this review was to evaluate the effect of perioperative dexmedetomidine on postoperative bowel recovery. Secondary aim was to evaluate the effect of dexmedetomidine on hospital discharge. EVIDENCE ACQUISITION: Randomized controlled trials in English language reporting any or all of the following parameters of bowel recovery; time to first bowel sounds, first flatus, first feces, or time to oral diet were included. EVIDENCE SYNTHESIS: Twelve hundred and thirty-five patients from 13 studies were analyzed. There were insufficient studies evaluating bowel sounds. Perioperative dexmedetomidine usage significantly reduced the time to first flatus [MD -5.61 h (95% CI: -8.61 to -2.60); P=0.0003; I2=95%], first feces [MD -12.70 h (95% CI: -19.11 to -6.29); P=0.0001; I2=76%] and the composite outcome of bowel recovery (flatus, feces, oral diet) [MD -7.44 h (95% CI: -10.31 to -4.57); P<0.00001; I2=96%]. No difference was seen in the time to oral diet [MD -6.29 h (95% CI: -13.48 to 0.91); P=0.09; I2=88%] or hospital discharge [MD -0.47 days (95% CI: -1.27 to 0.33); P=0.25; I2=86%]. CONCLUSIONS: Perioperative dexmedetomidine usage significantly shortens the time to first flatus, feces and composite bowel recovery but does not result in a shorter time to oral diet or earlier hospital discharge in adult patients receiving general anesthesia. Strength of evidence is however very low for the effect of dexmedetomidine on bowel recovery.

"Enhanced recovery after surgery - ERAS in elective craniotomies-a non-randomized controlled trial".

BACKGROUND: Enhanced Recovery After Surgery (ERAS) is a multimodal perioperative care bundle aimed at the early recovery of patients. Well accepted in gastric and pelvic surgeries, there is minimal evidence in neurosurgery and neurocritical care barring spinal surgeries. We wished to compare the length of intensive care unit (ICU) or high dependency unit (HDU) stay of patients undergoing elective craniotomy for supratentorial neurosurgery: ERAS protocol versus routine care. The secondary objective was to compare the postoperative pain scores, opioid use, glycemic control, and the duration of postoperative hospital stay between the two groups. METHODS: In this pragmatic non-randomized controlled trial (CTRI/2017/07/015451), consenting adult patients scheduled for elective supratentorial intracranial tumor excision were enrolled prospectively after institutional ethical clearance and consent. Elements-of-care in the ERAS group were- Preoperative -family education, complex-carbohydrate drink, flupiritine; Intraoperative - scalp blocks, limited opioids, rigorous fluid and temperature regulation; Postoperative- flupiritine, early mobilization, removal of catheters, and initiation of feeds. Apart from these, all perioperative protocols and management strategies were similar between groups. The two groups were compared with regards to the length of ICU stay, pain scores in ICU, opioid requirement, glycemic control, and hospital stay duration. The decision for discharge from ICU and hospital, data collection, and analysis was by independent assessors blind to the patient group. RESULTS: Seventy patients were enrolled. Baseline demographics - age, sex, tumor volume, and comorbidities were comparable between the groups. The proportion of patients staying in the ICU for less than 48 h after surgery, the cumulative insulin requirement, and the episodes of VAS scores > 4 in the first 48 h after surgery was significantly less in the ERAS group - 40.6% vs. 65.7%, 0.6 (±2.5) units vs. 3.6 (±8.1) units, and one vs. ten episodes (p = 0.04, 0.001, 0.004 respectively). The total hospital stay was similar in both groups. CONCLUSION: The study demonstrated a significant reduction in the proportion of patients requiring ICU/ HDU stay > 48 h. Better pain and glycemic control in the postoperative period may have contributed to a decreased stay. More extensive randomized studies may be designed to confirm these results. TRIAL REGISTRATION: Clinical Trial Registry of India ( CTRI/2018/04/013247 ), registered retrospectively on April 2018.

Nebulised fentanyl for post-operative pain relief, a prospective double-blind controlled randomised clinical trial.

BACKGROUND AND AIM: Intravenous (IV) route for fentanyl administration is the gold standard for post-operative pain relief, but complications such as respiratory depression, bradycardia and hypotension have limited this route. The aim of this randomised controlled trial was to compare the efficacy of nebulised fentanyl with IV fentanyl for post-operative pain relief after lower abdominal surgery. METHODS: In the post-operative care unit, at the time of first onset of pain (visual analogue scale- VAS score > 4) patients were randomised into three groups and fentanyl was administered either IV 2 µg/kg or by nebulisation of solution containing 3 or 4 µg/kg fentanyl over 8 min in 90 patients divided into three groups of 30 each. Observation were made for pain relief by visual analogue scale score 0-10. Adverse effects such as respiratory depression, bradycardia and hypotension were also recoded. Statistical analysis was performed using Medcalc software version 12, 2012. (MedCalc Software, Ostend, Belgium). RESULTS: In the nebulisation group, it was observed that the analgesic efficacy of fentanyl was dose dependent with a delayed onset of analgesia (10 min vs. 5 min). Nebulisation with 4 µg/kg fentanyl produced analgesia at par to 2 µg/kg IV fentanyl with prolonged duration (90 min vs. 30 min) and with significantly less adverse effects. CONCLUSIONS: This study shows that nebulisation with 4 µg/kg fentanyl may be used as an alternative to IV 2 µg/kg fentanyl for adequate post-operative pain relief.